Company / Cash & Equivalents
BioCardia, Inc. Cash & Equivalents History
FY2011-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$12.7M
FY2017
5-year range
$12.7M / $21.4M
FY2013-FY2017
Trend
-40.6%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$13M in FY2017.
Remained stable around $13M over the past 6 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2017, cash & equivalents decreased 40.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2017 | $12.7M | -40.6% |
| FY2016 | $21.4M | +68.4% |
| FY2011 | $12.7M | - |
As of FY2017 · SEC Form 10-K · Last checked Jun 21, 2026